METHOD FOR EVALUATING ADVERSE REACTION OF SESQUITERPENOIDS IN ZEDOARY TURMERIC OIL
20230251203 · 2023-08-10
Assignee
Inventors
Cpc classification
G01N21/75
PHYSICS
G01N21/31
PHYSICS
International classification
G01N21/75
PHYSICS
G01N21/31
PHYSICS
Abstract
A method for evaluating adverse reaction of sesquiterpenoids in zedoary turmeric oil is performed successively according to the following steps: (1) preparing a hemoglobin (Hb) solution and a to-be-determined solution; (2) taking Hb solutions with a same volume and respectively adding the same volume of the to-be-determined solution or normal saline thereto, mixing well and standing; (3) determining absorbance with a microplate reader, and comparing the absorbance of a to-be-determined solution group with the absorbance of a normal saline group to obtain a value r; wherein if r>1.5, then the result indicates that the concentration of the to-be-determined solution has a risk of causing dyspnea; wherein,
in the formula, OD is an absorbance at 280 nm wavelength of the to-be-determined solution after interacting with Hb; OD.sub.Hb, is an absorbance at 280 nm wavelength of a blank control of normal saline after interacting with Hb.
Claims
1. A method for evaluating an adverse reaction of sesquiterpenoids in a zedoary turmeric oil, wherein the method is performed successively according to the following steps: 1) preparing a hemoglobin (Hb) solution and a to-be-determined solution; 2) taking Hb samples from the Hb solution with a same volume and respectively adding the same volume of the to-be-determined solution or normal saline to each of the Hb samples, mixing well and standing; 3) determining an absorbance of each of the Hb samples and the to-be-determined solution with a microplate reader, and comparing the absorbance of the to-be-determined solution with the absorbance of a sample of the normal saline to obtain a value r; wherein if r>1.5, then a concentration of the to-be-determined solution has a risk of causing dyspnea; wherein,
2. The method according to claim 1, wherein in the step 1), the Hb solution has a concentration of 2 mg/mL.
3. The method according to claim 1, wherein in the step 2), the same volume of the to-be-determined solution or the normal saline added to each of the Hb samples is 100 μL.
4. The method according to claim 3, wherein the Hb samples has the same volume of 100 μL.
5. The method according to claim 1, wherein the step of mixing well in the step 2) is performed by using an oscillator for oscillation for 5 s.
6. The method according to claim 1, wherein the standing step in the step 2) is performed for 10 min at a condition of 25° C.
7. The method according to claim 1, wherein conditions for determining the absorbance of each of the Hb samples and the to-be-determined solution in the step 3) are as follows: performing a spectrum scanning at 37° C. and 230-400 nm with a step size of 5 nm.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0019]
[0020]
[0021]
[0022]
[0023]
[0024]
[0025]
[0026]
[0027]
[0028]
[0029]
[0030] In the drawing, * represents as follows: *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
DETAILED DESCRIPTION OF THE EMBODIMENTS
[0031] To further explain the technical means and results taken in this present invention to achieve the predetermined goals of the present invention, β-elemene in zedoary turmeric oil is set as an example in this present invention. The following preferred examples are used to describe the specific embodiments, technical solutions and features based on the present invention application hereafter. Specific features, structures, or characteristics of the multiple examples in the following description can be combined in any suitable form.
[0032] Main materials and sources selected and used in the following examples of the present invention are respectively as follows:
[0033] The sesquiterpenoid in zedoary turmeric oil, β-elemene (1S, 2S, 4R)-1-vinyl-methyl-2, 4-di(1-methylvinyl) cyclohexane, BE, has a structural formula shown in
Example I: Influences of β-Elemene (BE) on Blood Gas when Causes Dyspnea of Rats
[0034] Preparation of a BE solution: BE reference substances were precisely weighed and dissolved by 8.8% Tween 80 solution and prepared into a BE solution having a concentration of 1.5 mg/mL.
[0035] 12 pieces of SPF-grade SD male rats (6 weeks of age, weight: 200±25 g) were taken; and these rats were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd, production license number: SCXK (J.) 2016-0006.Animal experiments involved in the research process were approved by Ethics Committee. The feeding conditions of the experimental rats are as follows: standard illumination-dark period is 12 h, temperature is 22±1° C., and relative humidity is 60±5%.
[0036] The rats were randomly divided into 2 groups, 6 pieces each group. The rats were adaptively fed with common fodders for one week. Then the rats were subjected to overnight fasting (12 h), and then intraperitoneally injected with chloral hydrate (10 mg/mL, 4 mL/kg) for anesthetization. After anesthetization, the two groups were respectively injected with BE and normal saline via caudal vein with an administration volume of 6 mL/kg.
[0037] After administration, abdominal aortic blood was taken and immediately analyzed with a blood-gas analyzer. Results are shown in
[0038] After administration, it can be observed that the rats suffered obvious cyanosis of labium, cardiac acceleration, accelerated respiratory rate and increased breathing rate. After stopping administration, the rats had gradually decreased respiratory rate, and gradually reduced breathing rate, and then stabilized to a certain state, indicating that after injecting with BE, the rats suffered dyspnea symptoms, and got recovery automatically after stopping administration.
[0039] It can be seen from the results of
Example II: Verification of the Interaction Between β-Elemene and Hemoglobin
[0040] Surface plasmon resonance (SPR) technology was used to verify the interaction between β-elemene and hemoglobin. SPR may provide affinity for representing the interaction between small molecules and proteins (K.sub.D refers to a concentration of an analyte when 50% protein sites on a chip are saturated. The smaller the K.sub.D is, the stronger the affinity is, which namely indicates that both are bound with each other more easily). It is generally acknowledged that K.sub.D of binding protein to small molecules has an acceptable scope of 10.sup.−4-10.sup.−6M.
[0041] 1. Preparation of the Analyte
[0042] (1) Preparation of a Hb solution: a proper amount of Hb was weighed precisely and prepared into a solution having a concentration of 1 mg/mL with ultrapure water, then 20-fold diluted by pH 4.5 acetic acid for further use;
[0043] (2) PBS-P+10× was prepared into PBS-P+2.1× with ultrapure water, then a proper amount of DMSO was taken and prepared into PBS 2× containing 5% DMSO+0.1% Tween 20, and filtered for further use;
[0044] (3) A proper amount of BE reference substances were weighed precisely and dissolved into DMSO to be prepared into 10 mM solution, then the solution was diluted with PBS-P+2.1× to a reference substance solution containing 5% DMSO; and then the reference substance solution was diluted successively by 2× PBS-P+ to 100.00 μM, 50.00 μM, 25.00 μM, 12.50 μM, 6.25 μM, 3.12 μM. 1.56 μM and 0.78 μM and vortexed for 1 min, and then filtered by 0.22 μm filter membrane for further use.
[0045] 2. Preparation of a Calibration Solution
[0046] The calibration solution was prepared by the following tables:
TABLE-US-00001 4.5% DMSO 5.8% DMSO 2.1 × PBS-P+/1.05 × PBS-P+ 9.5 mL 9.5 mL 100% DMSO 0.45 mL 0.58 mL Final volume About 10 mL About 10 mL
TABLE-US-00002 4.9% DMSO 5.3% DMSO 4.5% DMSO 0.8 mL 0.4 mL 5.8% DMSO 0.4 mL 0.8 mL Final volume 1.2 mL 1.2 mL
[0047] 3. Preparation of a Washing Solution
[0048] 50% DMSO (ultrapure water and filtered DMSO (1:1)) washing solution was prepared to wash needles.
[0049] 4. Experimental Procedures
[0050] (1) Chip activation: carboxyl (channels 1 and 2) on a chip was activated by EDC/NHS;
[0051] (2) the channel 2 was selected and coupled to a certain amount of Hb;
[0052] (3) the activated carboxyl not coupled to proteins on the chip was blocked by ethanolamine;
[0053] (4) a flow channel system was washed by 2×PBS-P+running buffer;
[0054] (5) the prepared BE solution and washing solution were put on a shelf successively, and then put on a tray of the shelf for further sample injection;
[0055] (6) procedures were set to collect data.
[0056] SPR results are shown in
Example III: Influences of β-Elemene on Hb Structure
[0057] A circular dichroism spectrum technology (CD) was used to determine the influences of β-elemene on Hb structure.
[0058] Hb mainly presents α-helix at 200-250 nm. If the α-helix structure is changed, so do the shape of CD curve at 200-250 nm. The α-helix content of Hb at 222 nm may be calculated according to the equation (1):
[0059] The mean residue ellipticity (MRE) (degcm.sup.2/dmol) is calculated according to the equation (2):
[0060] where, Cp is molar concentration (mM) of Hb; n is the number of amino acid residues; l is optical path (mm).
[0061] Preparation of a PBS solution: a proper amount of PBS buffer solution was taken and added a small amount of Tween 80, then prepared into a PBS solution containing 0.05% Tween 80.
[0062] Preparation of a Hb solution: a proper amount of Hb was weighed precisely and added a proper amount of PBS containing 0.05% Tween 80, then prepared into Hb having a concentration of 30 μM for further use.
[0063] Preparation of a BE solution: a proper amount of BE was weighed precisely and added PBS containing 0.05% Tween 80, then prepared into a stock solution having a concentration of 15 μM for further use.
[0064] Preparation of a Hb+BE solution: a proper amount of BE and Hb were taken and prepared into a solution having a total volume of 1.5 mL, such that Hb had a final concentration of 5 μM; the BE final concentration was respectively 6.25 μM, 5.00 μM, 2.00 μM, 1.00 μM. 0.
[0065] Wavelength detection: 200-250 nm; step size: 0.5 nm; temperature: 25° C.; and response time: 0.5 s.
[0066] Operating Steps:
[0067] (1) the PBS solution containing 0.05% Tween 80 was first placed into a quartz sample pool having an optical path of 0.1 cm, and the sample pool was put to a sample chamber for detection, and screening was performed for 3 times to obtain a blank curve;
[0068] (2) each concentration of sample was placed into a quartz sample pool from small to large (during solution exchange, the sample pool was cleaned by PBS and rinsed with the to-be-detected solution), then the sample pool was put to the sample chamber for detection in turn, and each sample was screened by spectrum for 3 times;
[0069] (3) data analysis: the three times of scanning curves for each concentration are averaged, and the blank curve was respectively subtracted for background correction. Results are shown in
[0070] The detection results are shown in
Example IV: Evaluation on Adverse Reaction Caused by Sesquiterpenoids in Zedoary Turmeric Oil
[0071] The above examples have discussed the mechanism of adverse reaction of dyspnea caused by sesquiterpenoids in zedoary turmeric oil. Based on this, a method for evaluating adverse reaction caused by sesquiterpenoids in zedoary turmeric oil is put forward.
[0072] Preparation of Hb solution: a proper amount of Hb was precisely weighed and dissolved by normal saline (ultrasonic treatment for 30 s), and prepared into a solution having a concentration of 2 mg/mL.
[0073] Preparation of a BE solution: BE reference substance is precisely weighed and dissolved by 8.8% Tween 80 solution and prepared into a solution having a concentration of 1.5 mg/mL.
[0074] Specific Operation:
[0075] 100 μL Hb solution was added to wells of a 96-well plate, and 100 μL BE sample solution, 100 μL 8.8% Tween 80 solution or 100 μL normal saline (as blank control) were successively added to the wells added with Hb solution. Each sample was repeated with 3 wells; then the microwell plate was covered, and the mixed solution was oscillated for 5 s in an oscillator to be mixed well, standing for 10 min at 25° C. A microplate reader was used for detection, and detection conditions were as follows: spectrum scanning was performed at 37° C. and 230-400 nm with a step size of 5 nm.
[0076] The result curve is shown in
[0077] It can be seen from
[0078] From what has been discussed above, a method for evaluating adverse reaction of dyspnea caused by sesquiterpenoids in zedoary turmeric oil is put forward. It is shown by the following formula (3):
[0079] Where, OD is an absorbance value of a to-be-detected sample containing sesquiterpenoids in zedoary turmeric oil at a certain concentration at 280 nm after interacting with Hb; OD.sub.Hb is an absorbance value of normal saline as a blank control at a wavelength of 280 nm after interacting with Hb; r is a ratio of OD to OD.sub.Hb. In this formula, when r>1.5, the result indicates that the sample containing sesquiterpenoids in zedoary turmeric oil at the concentration can bind to Hb, and there is a high risk of dyspnea in clinical use.
[0080] For example, as shown in
[0081] Hereby, the present invention judges the risk of dyspnea in clinical use according to the r value obtained by interacting a medicament or relevant formulation containing sesquiterpenoids in zedoary turmeric oil thereof with Hb, thus achieving the early warning to the adverse reaction of dyspnea caused by sesquiterpenoids in zedoary turmeric oil, or a medicament or relevant formulation containing the component.
[0082] What is described above are merely preferred embodiments of the present invention, but the protection scope of the present invention is not limited thereto. Any equivalent replacement or change made by a person skilled in the art based on the technical solution and improvement concept of the present invention within the technical scope disclosed herein shall be covered within the protection scope of the present invention.